MedDataX Logo

AUGMENTIN 1gm In Skin And Soft Tissue Infection

NCT ID: NCT00343135

Last Updated: 2012-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

195 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-12-31

Study Completion Date

2005-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to evaluate the effects of AUGMENTIN 1gm in the treatment of Skin and Soft tissue infections

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Diseases, Infectious Infection, Soft Tissue

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Skin AUGMENTIN 1gm Soft tissue Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ARM 1

Group Type EXPERIMENTAL

amoxicillin/clavulanate potassium 1gm

Intervention Type DRUG

amoxicillin/clavulanate potassium 1gm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

amoxicillin/clavulanate potassium 1gm

amoxicillin/clavulanate potassium 1gm

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* having diagnosed uncomplicated soft tissue infection (e.g furuncle, cellulitis)
* has given freely documented consent.

Exclusion Criteria

* antibiotics
* have renal or hepatic insufficiency
* systemic toxicity
* pregnancy
* lactation
* hypersensitivity to penicillin or Beta-lactam antibiotics
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Karachi, , Pakistan

Site Status

GSK Investigational Site

Lahore, , Pakistan

Site Status

GSK Investigational Site

Lahore, , Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

103997

Identifier Type: -

Identifier Source: org_study_id